Developer docs
API playgroundTry for free, no card

Search company profiles

Cergentis

Full company profile

uuid000569j

Namestring
Cergentis
Legal namestring
Cergentis B.V.
Websiteurl
cergentis.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Cergentis B.V. is a Netherlands-domiciled biotechnology company that built its business around a proprietary Targeted Locus Amplification (TLA) technology platform used for genetic characterization and quality control (QC) testing of cell lines employed in biopharmaceutical manufacturing. The TLA platform enables targeted sequencing of genomic loci of interest and is positioned as a tool for assessing genetic stability of production cell lines and supporting the development of safe and effective advanced therapies, with particular emphasis on cell and gene therapy (CGT) programs.

In 2022, Cergentis was acquired by Solvias AG, a Swiss-headquartered contract research organization (CRO) with a 25-year track record serving pharmaceutical and biotech innovators. Following the acquisition, Cergentis' operations were progressively integrated into Solvias, and by 2024 the Cergentis service line is delivered under the Solvias brand while the Cergentis name and scientific team continue to be referenced for genetic QC work. Within Solvias' broader portfolio, the TLA-based offering sits alongside analytical method development and validation, cGMP drug substance and drug product testing, biosafety testing, extractables and leachables, stability testing, and impurity/contamination control services — covering the drug development journey from initial investigation through commercialization.

Cergentis operates as a B2B professional services line. Pricing is quote-based and contract-specific. The go-to-market is enterprise-led, relying on direct sales and account management, supported by industry conferences, scientific publications, and content marketing. The primary customer segments are biologics developers and companies developing cell and gene therapies; a secondary segment comprises small molecule developers using Solvias' broader analytical services. Via Solvias, the combined entity serves 700 customers worldwide, including 19 of the top 20 global pharmaceutical companies, with a workforce of 800+ (including 175+ PhD-level scientists) across Europe and the United States.

Short descriptiontext

Cergentis B.V., now part of Solvias, provides proprietary Targeted Locus Amplification (TLA)-based genetic characterization and quality control services for cell lines used in biopharmaceutical manufacturing, primarily serving biologics and cell/gene therapy developers worldwide.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic characterization services, cell line QC testing, targeted locus amplification, biologics analytical services, cell line genetic stability
Industry3 codes
PRIMARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Contract Research Organization (CRO) Services - Biopharmaceutical Analytical Testing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

CMC analytical testing services for pharmaceutical and biotech companies. Provides comprehensive analytical solutions from raw materials to drug products, including genetic quality control testing and release services.

solvias.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cergentis specializes in genetic characterization and quality control testing for cell lines used in biopharmaceutical manufacturing and advanced therapy development, using its proprietary Targeted Locus Amplification (TLA) technology platform. The company delivers comprehensive genetic stability assessment and QC services to pharmaceutical and biotech companies developing biologics, cell therapies, and gene therapies. Services are now offered through parent company Solvias as part of its broader CMC analytical services platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cergentis, now part of Solvias, offers a specialized portfolio centered on its proprietary Targeted Locus Amplification (TLA) technology platform. The company provides genetic characterization and quality control services primarily for cell lines used in biopharmaceutical and advanced therapy development. As part of Solvias' broader CMC analytical services offering, Cergentis services complement capabilities including analytical method development, cGMP testing, and biosafety testing. The TLA platform and genetic QC services form a distinct offering focused on genetic stability assessment for biologics and cell/gene therapy development.

Product and service1 record
1Genetic Quality Control Testing
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagship - Cergentis Was Acquired By Solvias In 2022 To Bolster Biologics And Cell & Gene Therapy Capabilities. The Acquisition Integrates Cergentis Into Solvias' Comprehensive Cmc Analytical Services Platform.TypeStrategic or Co-development Partner
Description

Cergentis was acquired by Solvias in 2022. This acquisition brought Cergentis' Targeted Locus Amplification (TLA) technology platform and expertise in genetic characterization and QC to Solvias. The partnership supports Solvias' strategy to provide comprehensive solutions for pharmaceutical developers from initial investigation to commercialization.

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

GenScript ProBio provides cell line development, plasmid manufacturing, and analytical testing for biologics including CGT. Its analytical services for cell line genetic stability and viral clearance are a direct partial overlap with Cergentis' TLA-based QC value proposition.

TypeBroad incumbent
Description

BioReliance is the legacy brand of Merck's biosafety testing and characterization services, offering cell line genetic characterization, viral clearance, and biosafety testing to pharma and CGT developers. It directly competes with Cergentis' TLA-based QC services while also offering a far broader testing portfolio under Merk's Life Sciences segment.

TypeBroad incumbent
Description

Eurofins is a global testing services group with pharma product testing, genomics, and bioanalytical capabilities acquired through multiple bolt-ons. It is a comparable broad CRO doing genetic characterization, release testing, and cell line QC for biologics developers, though at a much larger scale than Cergentis.

TypeBroad incumbent
Description

Intertek provides pharmaceutical contract lab services including CMC, biologics characterization, and release testing. Comparable to Cergentis as a high-quality analytical partner for drug developers, with a global footprint and broader service catalog.

TypeBroad incumbent
Description

Charles River offers a Biologics Testing Services portfolio including cell line characterization, lot release, and biosafety testing for advanced therapies. It is a directly comparable CRO for biopharma QC, with a broader discovery and CDMO footprint.

TypeDirect peer
Description

WuXi AppTec's Advanced Therapies unit provides testing, characterization, and manufacturing for cell and gene therapies. It competes with Cergentis in CGT-focused genetic QC and release testing, particularly for U.S.-based biotech sponsors.

TypeDirect peer
Description

Lonza is a leading CDMO with analytics, cell & gene therapy manufacturing, and extensive testing services. Its bioanalytics and CGT testing platform overlaps directly with Cergentis' offering, while Lonza adds manufacturing scale that Cergentis does not.

TypeEmerging player
Description

Sartorius offers analytical tools and services for cell line development, including genetic stability testing through its product portfolio. As a bioprocess supplier expanding into analytical services, Sartorius is an emerging peer with overlapping capability but narrower service orientation.

TypeDirect peer
Description

Catalent provides cell and gene therapy development, analytical services, and manufacturing. Its Cell & Gene Therapy analytical services overlap with Cergentis' genetic characterization and QC for cell lines and advanced therapies.

TypeBroad incumbent
Description

SGS is a global TIC (testing, inspection, certification) group with a dedicated Life Sciences division providing analytical and bioanalytical services to pharma customers, including biologics characterization and QC testing. It is a broad incumbent with overlapping biopharma analytical services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cergentis

Contract Research Organization (CRO) Services - Biopharmaceutical Analytical Testingcergentis.com

Cergentis B.V., now part of Solvias, provides proprietary Targeted Locus Amplification (TLA)-based genetic characterization and quality control services for cell lines used in biopharmaceutical manufacturing, primarily serving biologics and cell/gene therapy developers worldwide.

What Cergentis does

Cergentis B.V. is a Netherlands-domiciled biotechnology company that built its business around a proprietary Targeted Locus Amplification (TLA) technology platform used for genetic characterization and quality control (QC) testing of cell lines employed in biopharmaceutical manufacturing. The TLA platform enables targeted sequencing of genomic loci of interest and is positioned as a tool for assessing genetic stability of production cell lines and supporting the development of safe and effective advanced therapies, with particular emphasis on cell and gene therapy (CGT) programs.

In 2022, Cergentis was acquired by Solvias AG, a Swiss-headquartered contract research organization (CRO) with a 25-year track record serving pharmaceutical and biotech innovators. Following the acquisition, Cergentis' operations were progressively integrated into Solvias, and by 2024 the Cergentis service line is delivered under the Solvias brand while the Cergentis name and scientific team continue to be referenced for genetic QC work. Within Solvias' broader portfolio, the TLA-based offering sits alongside analytical method development and validation, cGMP drug substance and drug product testing, biosafety testing, extractables and leachables, stability testing, and impurity/contamination control services — covering the drug development journey from initial investigation through commercialization.

Cergentis operates as a B2B professional services line. Pricing is quote-based and contract-specific. The go-to-market is enterprise-led, relying on direct sales and account management, supported by industry conferences, scientific publications, and content marketing. The primary customer segments are biologics developers and companies developing cell and gene therapies; a secondary segment comprises small molecule developers using Solvias' broader analytical services. Via Solvias, the combined entity serves 700 customers worldwide, including 19 of the top 20 global pharmaceutical companies, with a workforce of 800+ (including 175+ PhD-level scientists) across Europe and the United States.

Cergentis firmographics

Firmographics
Name
Cergentis
Legal name
Cergentis B.V.
Website
https://cergentis.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cergentis B.V., now part of Solvias, provides proprietary Targeted Locus Amplification (TLA)-based genetic characterization and quality control services for cell lines used in biopharmaceutical manufacturing, primarily serving biologics and cell/gene therapy developers worldwide.
Ownership category
akta.pro rank

Cergentis industry classification

Industry
Product category
Contract Research Organization (CRO) Services - Biopharmaceutical Analytical Testing
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAGAF
Analytical Development & QC Testing (Release/Stability/Potency)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Genetic characterization services
  • Cell line QC testing
  • Targeted locus amplification
  • Biologics analytical services
  • Cell line genetic stability

Where Cergentis is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Cergentis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Organization Services: CMC analytical testing services for pharmaceutical and biotech companies. Provides comprehensive analytical solutions from raw materials to drug products, including genetic quality control testing and release services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Cergentis product offering

Product offering

Core offering

Cergentis specializes in genetic characterization and quality control testing for cell lines used in biopharmaceutical manufacturing and advanced therapy development, using its proprietary Targeted Locus Amplification (TLA) technology platform. The company delivers comprehensive genetic stability assessment and QC services to pharmaceutical and biotech companies developing biologics, cell therapies, and gene therapies. Services are now offered through parent company Solvias as part of its broader CMC analytical services platform.

Product overview

Cergentis, now part of Solvias, offers a specialized portfolio centered on its proprietary Targeted Locus Amplification (TLA) technology platform. The company provides genetic characterization and quality control services primarily for cell lines used in biopharmaceutical and advanced therapy development. As part of Solvias' broader CMC analytical services offering, Cergentis services complement capabilities including analytical method development, cGMP testing, and biosafety testing. The TLA platform and genetic QC services form a distinct offering focused on genetic stability assessment for biologics and cell/gene therapy development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Quality Control Testing

Companies that use Cergentis

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Cergentis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cergentis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Solvias AGflagship - cergentis was acquired by solvias in 2022 to bolster biologics and cell & gene therapy capabilities. the acquisition integrates cergentis into solvias' comprehensive cmc analytical services platform.Strategic or Co-development PartnerCergentis was acquired by Solvias in 2022. This acquisition brought Cergentis' Targeted Locus Amplification (TLA) technology platform and expertise in genetic characterization and QC to Solvias. The partnership supports Solvias' strategy to provide comprehensive solutions for pharmaceutical developers from initial investigation to commercialization.

Scale indicators4 records

Expansion highlights4 records

Cergentis competitors and assessment

Company assessment

Emerging players

  • GenScript ProBio: GenScript ProBio provides cell line development, plasmid manufacturing, and analytical testing for biologics including CGT. Its analytical services for cell line genetic stability and viral clearance are a direct partial overlap with Cergentis' TLA-based QC value proposition.
  • Sartorius Cell Line Development & QC: Sartorius offers analytical tools and services for cell line development, including genetic stability testing through its product portfolio. As a bioprocess supplier expanding into analytical services, Sartorius is an emerging peer with overlapping capability but narrower service orientation.

Broad incumbents

  • BioReliance (MilliporeSigma / Merck KGaA): BioReliance is the legacy brand of Merck's biosafety testing and characterization services, offering cell line genetic characterization, viral clearance, and biosafety testing to pharma and CGT developers. It directly competes with Cergentis' TLA-based QC services while also offering a far broader testing portfolio under Merk's Life Sciences segment.
  • Eurofins Scientific: Eurofins is a global testing services group with pharma product testing, genomics, and bioanalytical capabilities acquired through multiple bolt-ons. It is a comparable broad CRO doing genetic characterization, release testing, and cell line QC for biologics developers, though at a much larger scale than Cergentis.
  • Intertek Pharmaceutical Services: Intertek provides pharmaceutical contract lab services including CMC, biologics characterization, and release testing. Comparable to Cergentis as a high-quality analytical partner for drug developers, with a global footprint and broader service catalog.
  • Charles River Laboratories: Charles River offers a Biologics Testing Services portfolio including cell line characterization, lot release, and biosafety testing for advanced therapies. It is a directly comparable CRO for biopharma QC, with a broader discovery and CDMO footprint.
  • SGS Life Sciences: SGS is a global TIC (testing, inspection, certification) group with a dedicated Life Sciences division providing analytical and bioanalytical services to pharma customers, including biologics characterization and QC testing. It is a broad incumbent with overlapping biopharma analytical services.

Direct peers

  • WuXi Advanced Therapies Unit: WuXi AppTec's Advanced Therapies unit provides testing, characterization, and manufacturing for cell and gene therapies. It competes with Cergentis in CGT-focused genetic QC and release testing, particularly for U.S.-based biotech sponsors.
  • Lonza Cell & Gene Technologies: Lonza is a leading CDMO with analytics, cell & gene therapy manufacturing, and extensive testing services. Its bioanalytics and CGT testing platform overlaps directly with Cergentis' offering, while Lonza adds manufacturing scale that Cergentis does not.
  • Catalent (Novo Holdings): Catalent provides cell and gene therapy development, analytical services, and manufacturing. Its Cell & Gene Therapy analytical services overlap with Cergentis' genetic characterization and QC for cell lines and advanced therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cergentis social profiles

Digital presence

Cergentis compliance and trust

Trust signal

Compliance1 record

Cergentis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cergentis leadership team

Management profile

Number of profiles

Cergentis funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cergentis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cergentis

What does Cergentis do?

Cergentis specializes in genetic characterization and quality control testing for cell lines used in biopharmaceutical manufacturing and advanced therapy development, using its proprietary Targeted Locus Amplification (TLA) technology platform. The company delivers comprehensive genetic stability assessment and QC services to pharmaceutical and biotech companies developing biologics, cell therapies, and gene therapies. Services are now offered through parent company Solvias as part of its broader CMC analytical services platform.

When was Cergentis founded?

Cergentis was founded in 2012. It employs 11 to 50 people.

Where is Cergentis based?

Cergentis is headquartered in Utrecht, Netherlands, in the Europe region.

How does Cergentis make money?

One revenue line is on record: contract Research Organization Services.

Who are Cergentis's main competitors?

Emerging players on record are GenScript ProBio and Sartorius Cell Line Development & QC. Broad incumbents are BioReliance (MilliporeSigma / Merck KGaA), Eurofins Scientific, Intertek Pharmaceutical Services, Charles River Laboratories and SGS Life Sciences. Direct peers are WuXi Advanced Therapies Unit, Lonza Cell & Gene Technologies and Catalent (Novo Holdings).

Does Cergentis have an API?

No public API is recorded for Cergentis.

What industry is Cergentis in?

Cergentis's product category is Contract Research Organization (CRO) Services - Biopharmaceutical Analytical Testing. Its primary akta.pro industry code is HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSolvias erwirbt Cergentis und stärkt damit die Kapazitäten in den Bereichen Biologika sowie Zell- und GentherapieSolvias, a world-leading independent pharmaceutical testing and manufacturing company headquartered in Switzerland, has acquired Cergentis, a genomics-focused biotechnology company based in Utrecht, Netherlands, to strengthen its testing capabilities for biologics and cell and gene therapies. The acquisition provides Solvias with proprietary genomic analysis technology and a highly scientific team to support the growing number of pharmaceutical, biotech, and contract development companies developing genetically modified therapies. Cergentis is Solvias's second acquisition since merging with investors Water Street Healthcare Partners and JLL Partners in 2020, with financial terms undisclosed.PR NewswireSolvias acquiert Cergentis pour renforcer ses capacités en matière de produits biologiques et de thérapie cellulaire et géniqueSolvias, a global pharmaceutical testing and manufacturing company, has acquired the Dutch firm Cergentis to expand its capabilities in biological products and cell and gene therapy. This strategic move allows Solvias to offer proprietary genomic analysis technology and specialized services to support the validation of safety and efficacy for advanced therapies. The acquisition aligns with the projected rapid growth of the cell and gene therapy market, which is expected to grow at a compound annual growth rate of 63% through 2026.PR NewswireSolvias neemt Cergentis over om de capaciteiten op het gebied van biologica en cel- en gentherapie te versterkenSolvias, a leading global pharmaceutical testing and manufacturing company headquartered in Switzerland, has acquired Netherlands-based Cergentis to expand its biologics and cell and gene therapy testing capabilities. The acquisition adds Cergentis' proprietary genomic analysis platform and expertise to Solvias' portfolio, positioning the combined entity to serve the rapidly growing cell and gene therapy market, which is projected to expand at a 63% compound annual growth rate through 2026. Joris Schuurmans, CEO of Cergentis, will join Solvias' leadership team following the acquisition, while financial terms remain undisclosed.PR NewswireSolvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy CapabilitiesSolvias has acquired Netherlands-based Cergentis to expand its biologics and cell & gene therapy testing capabilities. This strategic move allows Solvias to integrate Cergentis's proprietary genomic analysis technology and expertise, supporting the rapidly growing market for advanced therapies which is projected to grow at a 63% compound annual growth rate through 2026.BioSpaceSolvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy CapabilitiesSolvias has acquired Utrecht-based Cergentis to expand its biologics and cell & gene therapy testing capabilities. This strategic move allows Solvias to integrate Cergentis's proprietary genomic analysis technology and expert team into its platform, supporting the rapid growth of the advanced therapies market.PR NewswireCergentis receives ISO/IEC 17025:2017 accreditationCergentis, a biotechnology company based in Utrecht, Netherlands, announced it has received ISO/IEC 17025:2017 accreditation for its genetic quality control services based on Targeted Locus Amplification technology. The accreditation demonstrates that the company's QC services operate within internationally recognized quality standards required by its customers in the biopharmaceutical and research sectors. CEO Joris Schuurmans stated the recognition represents a milestone that underscores the company's commitment to quality and its mission to advance genetic research.PR NewswireCergentis introduces in-house solution for CHO clone selectionCergentis, a genomics company based in Utrecht, Netherlands, announced the launch of CHOice, its first fully integrated in-house solution for Chinese Hamster Ovary (CHO) clone selection used in biopharmaceutical cell line development. The solution combines a reagents kit, proprietary software platform for automated variant calling and reporting, technical support, and expert consultation to enable customers to perform TLA-based genetic quality control independently. The company stated the platform addresses limitations of conventional technologies by providing comprehensive genetic characteristics in a single test with faster turnaround times and reduced costs.PR NewswireNew revolutionary tool for cancer diagnosticsCergentis announced successful analytical validation of its Targeted Locus Amplification (TLA) technology (FFPE-TLC) for detecting clinically relevant translocations in lymphoma tumor biopsies, with results published in the peer-reviewed journal Nature Communications. The validation study was conducted in collaboration with researchers from the Hubrecht Institute and five Dutch pathology laboratories, demonstrating superior performance over the standard FISH method with better sensitivity and higher resolution. The company, which developed the technology with support from an EU Horizon 2020 SME grant, plans to make FFPE-TLC available to pathology labs to improve lymphoma and other cancer diagnostics.PR NewswireCergentis Expands Product PortfolioCergentis, a genomics company headquartered in Utrecht, Netherlands, announced the expansion of its product portfolio with two new service packages for cell line development: a clonality assurance package and a genetic stability package. The packages utilize Cergentis' proprietary Targeted Locus Amplification (TLA) technology to provide genetic analysis for producer cell lines used in pharmaceutical biologic production, addressing regulatory requirements from FDA and EMA. CEO Joris Schuurmans stated the new packages address increasing customer demand and expand the company's TLA-based genetic engineering portfolio.